Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5620989 | 1.00 | MAPT (0.40) | MAPTRAB9ASMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL6159528 | 0.83 | — | — | |
| SCHEMBL3145148 | 0.80 | MAPT (0.40) | MAPTRAB9ASMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL10384639 | 0.80 | MAPT (0.40) | MAPTRAB9ASMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL16135393 | 0.78 | RAB9A (0.39) | MAPTRAB9ASMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL10383886 | 0.75 | — | — | |
| SCHEMBL2464131 | 0.75 | MAPT (0.52) | MAPTRAB9ASMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL2464133 | 0.75 | MAPT (0.52) | MAPTRAB9ASMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL23345540 | 0.74 | GAA (0.42) | MAPTRAB9AALDH1A1GAATSHR | |
| SCHEMBL16135277 | 0.74 | GAA (0.42) | MAPTRAB9AALDH1A1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | TEIJIN PHARMA LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1666067-A1 | DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT | Teijin Pharma Limited (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-0826671-B1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-6528514-B1 | Pyrimidin-4-one-5-amino-3-alkylcarboxamidomethyl compounds | WELFIDE CORPORATION (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1062949-A1 | IgE ANTIBODY PRODUCTION INHIBITORS AND AUTOIMMUNE DISEASES INHIBITORS | Welfide Corporation (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-6080738-A | USEFUL AS CHYMASE INHIBITORS AND CAN BE USED FOR THE PROPHYLAXIS AND TREATMENT OF VARIOUS DISEASES CAUSED BY CHYMASE, SUCH AS THOSE CAUSED BY ANGIOTENSIN II | YOSHITOMI PHARMACEUTICALS INDUSTRIES, LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| EP-0940400-A1 | NOVEL HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USES THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5948785-A | USEFUL AS CHYMASE INHIBITORS AND CAN BE EFFECTIVE FOR THE PROPHYLAXIS AND TREATMENT OF VARIOUS DISEASES CAUSED BY CHYMASE, SUCH AS THOSE CAUSED BY ANGIOTENSIN II. | THE GREEN CROSS CORPORATION (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0826671-A1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | THE GREEN CROSS CORPORATION (JP) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | REN, SERPINB1, CMA1 | MAPT 1795/4885RAB9A 1216/4885SMN1; SMN2 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.